[go: up one dir, main page]

MX2023007265A - Inhibidores de cdk y su uso como productos farmacéuticos. - Google Patents

Inhibidores de cdk y su uso como productos farmacéuticos.

Info

Publication number
MX2023007265A
MX2023007265A MX2023007265A MX2023007265A MX2023007265A MX 2023007265 A MX2023007265 A MX 2023007265A MX 2023007265 A MX2023007265 A MX 2023007265A MX 2023007265 A MX2023007265 A MX 2023007265A MX 2023007265 A MX2023007265 A MX 2023007265A
Authority
MX
Mexico
Prior art keywords
pharmaceutical products
cdk inhibitors
compounds
formula
cdk
Prior art date
Application number
MX2023007265A
Other languages
English (en)
Inventor
Andrew W Buesking
Andrew Paul Combs
Ryan Holmes
Sarah Pawley
Xiaowei Wu
Katarina Rohlfing
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of MX2023007265A publication Critical patent/MX2023007265A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La descripción se dirige a compuestos de la Fórmula (I), también se describen composiciones farmacéuticas que comprenden compuestos de la Fórmula (I), así como métodos para su uso y preparación. (ver fórmula I).
MX2023007265A 2020-12-18 2021-12-17 Inhibidores de cdk y su uso como productos farmacéuticos. MX2023007265A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063127853P 2020-12-18 2020-12-18
PCT/US2021/064037 WO2022133215A1 (en) 2020-12-18 2021-12-17 Cdk inhibitors and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
MX2023007265A true MX2023007265A (es) 2023-08-14

Family

ID=80050584

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007265A MX2023007265A (es) 2020-12-18 2021-12-17 Inhibidores de cdk y su uso como productos farmacéuticos.

Country Status (10)

Country Link
US (2) US12129262B2 (es)
EP (1) EP4263525A1 (es)
JP (1) JP2023554643A (es)
KR (1) KR20230122096A (es)
CN (1) CN116940563A (es)
AU (1) AU2021401403A1 (es)
CA (1) CA3205652A1 (es)
IL (2) IL316942A (es)
MX (1) MX2023007265A (es)
WO (1) WO2022133215A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114786673A (zh) 2019-09-11 2022-07-22 普莱鲁德疗法有限公司 Cdk抑制剂及其作为药物的用途
CA3197985A1 (en) * 2020-11-20 2022-05-27 Qingsong Liu Dihydroisoquinolinone and isoindolinone derivatives and uses thereof
US20230257394A1 (en) * 2022-02-03 2023-08-17 Prelude Therapeutics, Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
WO2024035771A2 (en) * 2022-08-09 2024-02-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Ulk3 inhibitors and uses thereof
WO2024051717A1 (zh) * 2022-09-08 2024-03-14 上海深势唯思科技有限责任公司 作为plk1抑制剂的化合物及其制备方法和用途
CN115594664B (zh) * 2022-11-25 2023-02-24 英矽智能科技(上海)有限公司 一类螺环衍生物作为kif18a抑制剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US8426417B2 (en) 2007-09-28 2013-04-23 Nerviano Medical Sciences S.R.L. Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
EP3665179B1 (en) 2017-08-09 2021-06-09 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
CN110684861B (zh) 2018-07-05 2023-10-27 上海公卫生物医药有限公司 一种用于bkv的早期诊断和检测体系及其应用
CN113661164B (zh) * 2019-04-08 2025-03-04 珠海宇繁生物科技有限责任公司 一种cdk激酶抑制剂及其应用
EP4200296A1 (en) * 2020-08-20 2023-06-28 Hepagene Therapeutics (HK) Limited Mnk inhibitors

Also Published As

Publication number Publication date
IL303779B2 (en) 2025-04-01
WO2022133215A1 (en) 2022-06-23
US12129262B2 (en) 2024-10-29
EP4263525A1 (en) 2023-10-25
IL303779B1 (en) 2024-12-01
AU2021401403A9 (en) 2024-10-24
IL303779A (en) 2023-08-01
US20250163074A1 (en) 2025-05-22
CN116940563A (zh) 2023-10-24
KR20230122096A (ko) 2023-08-22
AU2021401403A1 (en) 2023-07-13
JP2023554643A (ja) 2023-12-28
CA3205652A1 (en) 2022-06-23
US20220267345A1 (en) 2022-08-25
IL316942A (en) 2025-01-01

Similar Documents

Publication Publication Date Title
MX2023007265A (es) Inhibidores de cdk y su uso como productos farmacéuticos.
MX2021005463A (es) Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1).
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
MX2020001598A (es) Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5).
ZA202304541B (en) Cdk inhibitors and their use as pharmaceuticals
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
BRPI1009333B8 (pt) compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica
BRPI0814065B8 (pt) derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
CY1119056T1 (el) Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna
MX374497B (es) Inhibidor del antígeno de superficie del virus de la hepatitis b.
MX2018007075A (es) Compuestos policiclicos como inhibidores de tirosina quinasa de bruton.
BR112013018515A2 (pt) derivados de pirrol tricíclico, processo para preparação e seu uso como inibidores da quinase
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
MX386166B (es) Derivados de piperidina 1,4-sustituidos.
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
MX386700B (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
MX2024002391A (es) Inhibidores de indolina de kif18a.
ZA202005325B (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
MX2025002929A (es) Compuestos de objetivo brm y metodos de uso asociados
UY39588A (es) Pirazolotiazol carboxamidas y usos de estas como inhibidores de pdgfr
CR20110703A (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt(pkb)